Volume 14 - Issue 6 - June 2006

Topical imiquimod 5% cream and 5-fluorouracil 0.5% microsphere cream are used for treatment of actinic keratosis. Yet to date, no blinded trials have directly compared the severity of symptoms associated with these two agents. Visible inflammation in the region of application is common during treatment with either of these therapies, although some literature has suggested that the severity of symptomatology (eg burning, stinging, pain) differs between the two agents. This article reports on application-site tolerability results from an investigator-blinded, 4-week, randomized,